Get More Information on CAR T-Cell Therapies Market - Request Sample Report
The CAR T-Cell Therapies Market was valued at USD 4.3 billion in 2023 and is expected to reach USD 35.2 billion by 2032 and grow at a CAGR of 26.0% over the forecast period of 2024-2032.
The CAR-T cell therapy market has been witnessing a tremendous boom due to some major driving factors such as cancer incidence, and product approvals as well as investment in the gene therapy space. Even with 2020, Cancer remains a significant global health issue with new cases worldwide exceeding 19 million and almost 10 million deaths caused by cancer, Globocan. The alarming trend has upped the stakes for intense and effective therapies like CAR-T, which has won more milestones than conventional therapies. Adoptive immunotherapy CAR-T is a form of therapy that modifies the T-cells of a patient to be able to target cancer cells more sensitively, an area of promise in conditions such as leukemia, lymphoma, and multiple myeloma.
Product Approvals have been one of the growth factors of the CAR-T market. These approvals of Yescarta, Tecartus, Kymriah, and Carvykti are expected to herald a shift away from the traditional treatment with small molecules and proteins toward cell therapies through adoption. For instance, market competition between companies has increased manifold since February 2022, when the U.S. FDA approved Yescarta as the first CAR-T therapy in relapsed or refractory large B-cell lymphoma (LBCL). The investments in manufacturing capacity, along with clinical research, have increased simultaneously with these approvals. More than 500 clinical trials involving CAR-T therapies have been conducted worldwide, with East Asia and the United States at the forefront of R&D. Particular momentum has been gained in the United States, particularly due to regulatory blessings and private investment.
Although the pandemic is already problematic to deal with and thus delays 2020's development of the CAR-T therapy market, delayed diagnoses of cancer and disruptions in health services indicated that the pandemic may have even impacted the count of blood cancer diagnoses, which decreased during this period because such diseases may overlap with symptoms of COVID-19. However, 2021 was a year of recovery as awareness increased and approval for extended indications for CAR-T therapies expanded.
The companies have been constantly scaling up their production capacity to meet the growing demand, and further developments in gene therapy platforms have led to significant investment in the CAR-T space. In this regard, Series B funding of USD 100 million for Ori Biotech in 2022 has accelerated the commercialization of new gene therapies and led to higher supply levels of CAR-T therapies. This strong demand and supply dynamics coupled with further innovation is anticipated to drive growth over the forecast period as well.
Drivers
Rising Prevalence of Hematological Cancers Drives Surge in CAR-T Cell Therapy Adoption
The rising prevalence of hematological cancers, such as non-Hodgkin’s lymphoma (NHL) and leukemia, is a critical driver for the growth of the CAR-T cell therapy market. With cancer cases expected to surge globally, the demand for innovative treatments like CAR-T therapy is on the rise. According to the International Agency for Research on Cancer (IARC), the global burden of cancer is projected to reach 27.5 million new cases by 2040, with 16.3 million cancer-related deaths. Similarly, the American Cancer Society estimates a significant increase in cancer cases, from 18.1 million in 2018 to 29.4 million by 2040, highlighting the growing need for advanced therapies.
Increased awareness about blood cancers, driven by initiatives from governments, healthcare agencies, and market players, is resulting in higher diagnosis and treatment rates. Patient Assistance Programs (PAPs) are also contributing to the wider adoption of CAR-T therapies by making treatments more accessible. The rising prevalence of non-Hodgkin’s lymphoma, in particular, is boosting the demand for CAR-T cell therapy. As reported by the American Society of Hematology, NHL is among the most common cancers, with 544,000 new cases and 260,000 deaths reported in 2022.
In addition, researchers are exploring new approaches like CRISPR gene-editing technology to enhance CAR-T therapies, further driving market growth. Overall, the increasing focus on developing novel therapies to treat blood cancers is expected to accelerate the adoption of CAR-T cell therapies during the forecast period.
Restraints
High Cost of Treatment Limits the Adoption of CAR-T Cell Therapy
By Drug Type:
The Axicabtagene Ciloleucel (Yescarta) segment dominated the CAR-T cell therapy market with a 24.2% share in 2023, primarily due to its wide range of applications and high efficacy in treating non-Hodgkin lymphoma (NHL). Yescarta, approved by the FDA as the first CAR-T therapy for relapsed or refractory large B-cell lymphoma (LBCL), has gained significant traction. Additionally, Tisagenlecleucel (Kymriah), another key player, is widely used for treating pediatric and young adult patients with acute lymphoblastic leukemia (ALL), further boosting its adoption.
However, Ciltacabtagene Autoleucel (Carvykti) is projected to be the fastest-growing drug type in the market. Approved in 2022 for multiple myeloma, Carvykti has shown remarkable efficacy in patients with relapsed or refractory cases, leading to growing demand. With a robust pipeline of clinical trials and expanding indications, this drug type is expected to witness the highest growth rate during the forecast period.
By Indication:
Non-Hodgkin Lymphoma (NHL) led the market with 38.4% in 2023 among the indications, primarily due to the higher prevalence of this cancer type and the availability of multiple CAR-T therapies, such as Yescarta, Kymriah, and Breyanzi, specifically targeting NHL. The established efficacy of these therapies in treating relapsed or refractory patients has cemented NHL as the dominant segment.
In contrast, multiple myeloma is anticipated to be the fastest-growing segment. Recent drug approvals like Carvykti and Abecma have significantly advanced treatment options for multiple myeloma, especially in patients who have exhausted traditional therapies. This surge in new treatments and ongoing clinical trials will likely propel the growth of the multiple myeloma segment.
By End-user:
Hospitals dominated the end-user segment in the CAR-T cell therapy market with a 42.9% share in 2023. Hospitals, due to their larger patient influx and advanced healthcare infrastructure, are better equipped to administer complex and expensive CAR-T therapies. They also play a pivotal role in facilitating clinical trials, further cementing their dominant position.
However, oncology treatment centers are forecasted to experience the fastest growth in the coming years. As specialized centers focusing exclusively on cancer treatment, these facilities are increasingly adopting CAR-T therapies due to their ability to provide tailored and advanced care to cancer patients. The rise in the number of such centers, along with advancements in treatment protocols, will likely boost their market share during the forecast period.
In 2023, North America accounted for approximately 63.8% of the CAR-T cell therapy market revenue, with the U.S. leading the global market. This dominance is primarily due to the region's strong research infrastructure, well-established commercial base, and the large number of ongoing clinical trials for T-cell therapies. The increasing number of regulatory approvals in both the U.S. and Canada, combined with a shifting reimbursement landscape, has further fueled the adoption of CAR-T therapies, contributing to significant market growth.
Meanwhile, the Asia Pacific region is poised to experience a rapid compound annual growth rate (CAGR) of over 30% during the forecast period. China, in particular, has emerged as a key player, boasting the highest number of registered clinical trials for CAR-T therapies. The country’s rapid growth is attributed to substantial government investments and healthcare reforms aimed at advancing cancer treatment. As a result, China is leading the Asia Pacific region in CAR-T market expansion, with the fastest projected CAGR in the coming years. Overall, the increasing focus on research, government support, and favorable regulatory environments across these regions are driving the growth of CAR-T cell therapy globally.
Need any customization research on CAR T-Cell Therapies Market - Enquiry Now
Novartis AG
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
CARsgenTherapeutics Co., Ltd
JW Therapeutics (Shanghai) Co., Ltd.
Aurora Biopharma
Novartis AG
Merck KGaA
Gilead Sciences Inc.
TCR2 Therapeutics Inc
Bluebird Bio Inc.
Sorrento Therapeutics
Fate Therapeutics
Pfizer Inc.
Celgene Corporation and others.
In May 2024, the U.S. FDA granted accelerated approval for BREYANZI (lisocabtagene maraleucel) to treat adult patients with relapsed or refractory Follicular Lymphoma (FL) who have undergone two or more prior lines of systemic therapy.
In April 2024, Bristol entered a global capacity reservation and supply agreement with Cellares to produce CAR T-cell therapies using Cellares’ automated, high-throughput manufacturing platform, Cell Shuttle.
In December 2023, Max Healthcare, in collaboration with ImmunoACT, launched CAR-T cell therapy in Delhi-NCR for the treatment of lymphomas and leukemias.
In January 2023, Gilead received U.S. FDA approval for modifications to the manufacturing processes of YESCARTA (axicabtagene ciloleucel), reducing the median turnaround time (TAT) in the U.S. from 16 days to 14 days.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 4.3 billion |
| Market Size by 2032 | US$ 35.2 billion |
| CAGR | CAGR of 26% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Type [Axicabtagene Ciloleucel (Yescarta), Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), Tisagenlecleucel (Kymriah), Others] • By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma) • By End-user (Hospitals, Oncology Treatment Centers) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Gilead Sciences, Inc. , Novartis AG , Bristol-Myers Squibb Company , Johnson & Johnson Services, Inc. (Janssen Global Services, LLC) , Caribou Biosciences, Inc. , CARsgenTherapeutics Co., Ltd , JW Therapeutics (Shanghai) Co., Ltd. , Cartesian Therapeutics, Inc. , Aurora Biopharma, Novartis AG, Others |
| Key Drivers | • Rising Prevalence of Hematological Cancers Drives Surge in CAR-T Cell Therapy Adoption |
| Market Restraints | • High Cost of Treatment Limits the Adoption of CAR-T Cell Therapy |
Ans: The projected market value of the CAR T-Cell Therapies market is estimated at USD 4.3 Billion in 2023 and is expected to reach USD 35.2 billion by 2032.
Ans: The estimated compound annual growth rate is 26.0% during the forecast period for the CAR T-Cell Therapies market.
Ans: The rising prevalence of hematological cancers, such as non-Hodgkin’s lymphoma (NHL) and leukemia, is a critical driver for the growth of the CAR-T cell therapy market.
Ans: The high cost of treatment limits the adoption of Car-t cell therapy.
Ans: North America is the dominant region in the CAR T-Cell Therapies market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. CAR T-Cell Therapies Market Segmentation, by Drug Type
7.1 Chapter Overview
7.2 Axicabtagene Ciloleucel (Yescarta)
7.2.1 Axicabtagene Ciloleucel (Yescarta) Market Trends Analysis (2020-2032)
7.2.2 Axicabtagene Ciloleucel (Yescarta) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Brexucabtagene Autoleucel (Tecartus)
7.3.1 Brexucabtagene Autoleucel (Tecartus) Market Trends Analysis (2020-2032)
7.3.2 Brexucabtagene Autoleucel (Tecartus) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Ciltacabtagene Autoleucel (Carvykti)
7.4.1 Ciltacabtagene Autoleucel (Carvykti) Market Trends Analysis (2020-2032)
7.4.2 Ciltacabtagene Autoleucel (Carvykti) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Idecabtagene Vicleucel (Abecma)
7.5.1 Idecabtagene Vicleucel (Abecma) Market Trends Analysis (2020-2032)
7.5.2 Idecabtagene Vicleucel (Abecma) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Lisocabtagene Maraleucel (Breyanzi)
7.6.1 Lisocabtagene Maraleucel (Breyanzi) Market Trends Analysis (2020-2032)
7.6.2 Lisocabtagene Maraleucel (Breyanzi) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Tisagenlecleucel (Kymriah)
7.7.1 Tisagenlecleucel (Kymriah)Market Trends Analysis (2020-2032)
7.7.2 Tisagenlecleucel (Kymriah)Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. CAR T-Cell Therapies Market Segmentation, by Indication
8.1 Chapter Overview
8.2 Acute Lymphoblastic Leukemia
8.2.1 Acute Lymphoblastic Leukemia Market Trends Analysis (2020-2032)
8.2.2 Acute Lymphoblastic Leukemia Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Non-Hodgkin Lymphoma
8.3.1 Non-Hodgkin Lymphoma Market Trends Analysis (2020-2032)
8.3.2 Non-Hodgkin Lymphoma Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Multiple Myeloma
8.4.1 Multiple Myeloma Market Trends Analysis (2020-2032)
8.4.2 Multiple Myeloma Market Size Estimates and Forecasts to 2032 (USD Million)
9. CAR T-Cell Therapies Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Oncology Treatment Centers
9.3.1 Oncology Treatment Centers Market Trends Analysis (2020-2032)
9.3.2 Oncology Treatment Centers Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.2.4 North America CAR T-Cell Therapies Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.5 North America CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.2.6.2 USA CAR T-Cell Therapies Market Estimates and Forecasts, by Indication (2020-2032) (USD Million)
10.2.6.3 USA CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.2.7.2 Canada CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.2.7.3 Canada CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.2.8.2 Mexico CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.2.8.3 Mexico CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.4 Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.5 Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.6.2 Poland CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.6.3 Poland CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.7.2 Romania CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.7.3 Romania CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.8.2 Hungary CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.8.3 Hungary CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.9.2 Turkey CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.9.3 Turkey CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.4 Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.5 Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.6.2 Germany CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.6.3 Germany CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.7.2 France CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.7.3 France CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.8.2 UK CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.8.3 UK CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.9.2 Italy CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.9.3 Italy CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.10.2 Spain CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.10.3 Spain CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.11.2 Netherlands CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.11.3 Netherlands CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.12.2 Switzerland CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.12.3 Switzerland CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.13.2 Austria CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.13.3 Austria CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.4 Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.5 Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.6.2 China CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.6.3 China CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.7.2 India CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.7.3 India CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.8.2 Japan CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.8.3 Japan CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.9.2 South Korea CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.9.3 South Korea CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.10.2 Vietnam CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.10.3 Vietnam CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.11.2 Singapore CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.11.3 Singapore CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.12.2 Australia CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.12.3 Australia CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.4 Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.5 Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.6.2 UAE CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.6.3 UAE CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.7.2 Egypt CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.7.3 Egypt CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.9.2 Qatar CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.9.3 Qatar CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.2.4 Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.5 Africa CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.2.6.2 South Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.6.3 South Africa CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.2.7.2 Nigeria CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.7.3 Nigeria CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.6.4 Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.5 Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.6.6.2 Brazil CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.6.3 Brazil CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.6.7.2 Argentina CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.7.3 Argentina CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.6.8.2 Colombia CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.8.3 Colombia CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by Drug Type (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by Indication(2020-2032) (USD Million)
10.6.9.3 Rest of Latin America CAR T-Cell Therapies Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Gilead Sciences, Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Novartis AG
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Bristol-Myers Squibb Company
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Johnson & Johnson Services, Inc. (Janssen Global Services, LLC)
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Caribou Biosciences, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Novartis AG
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Gilead Sciences Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 TCR2 Therapeutics Inc
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Sorrento Therapeutics
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Pfizer Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Drug Type
Axicabtagene Ciloleucel (Yescarta)
Brexucabtagene Autoleucel (Tecartus)
Ciltacabtagene Autoleucel (Carvykti)
Idecabtagene Vicleucel (Abecma)
Lisocabtagene Maraleucel (Breyanzi)
Tisagenlecleucel (Kymriah)
Others
By Indication
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
By End-user
Hospitals
Oncology Treatment Centers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The High Throughput Screening Market Size was valued at USD 25.80 billion in 2023 and is witnessed to reach USD 69.46 Billion by 2032 and grow at a CAGR of 12.18% over the forecast period 2024-2032.
The Omega-3 Fatty Acid Market Size was valued at USD 2.5 billion in 2023 and is expected to reach USD 4.8 billion by 2032, and grow at a CAGR of 7.4% over the forecast period 2024-2032.
Biopharmaceutical Excipients Market Size was Valued $2.7 billion in 2023 & is Expected to Reach $4.17 billion by 2031 & growing at a CAGR of 5.6% by 2024-2031
The Sequencing Market Size was valued at USD 13.0 Billion in 2023, and is expected to reach USD 47.29 Billion by 2032, and grow at a CAGR of 15.40% Over the forecast period of 2024-2032.
The Healthcare Claims Management Market size was valued at USD 32.99 billion in 2023 and is expected to reach USD 220.49 billion by 2032 and grow at a CAGR of 23.5% over the forecast period 2024-2032.
The Population Health Management Market Size was valued USD 71.83 Bn in 2023, & will reach USD 352.55 Bn by 2031, and grow at a CAGR of 22.07% by 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
